Latest imidazoles Stories

A team of Massachusetts General Hospital (MGH) physicians has developed a new general anesthetic that may be safer for critically ill patients. In the August issue of Anesthesiology, they describe preclinical studies of the drug called MOC-etomidate "“ a chemically altered version of an exiting anesthetic "“ which does not cause the sudden drop in blood pressure seen with most anesthetics or prolonged suppression of adrenal gland activity, a problem with the original version of the...

WOODCLIFF LAKE, N.J., June 10 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa is seeking approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and...

Gene overexpressed in up to 20 percent of breast cancers responds to blood pressure drug in lab, U-M researchers report Researchers have identified a gene that is overexpressed in up to 20 percent of breast cancers and that could be blocked in the lab by a currently available blood pressure drug, according to a new study from the University of Michigan Comprehensive Cancer Center.The gene, called AGTR1, caused normal breast cells to behave like cancer cells. This behavior was reversed by...

Reduce your blood pressure "“ cut your risk for breast cancer? New research shows a common blood pressure drug can block a breast cancer gene.Losartan is prescribed to treat patients with high blood pressure. But in a recent study on mice, researchers found it blocked the gene AGTR1, a gene seen in 10 to 20 percent of breast cancers that causes normal breast cells to behave like cancer cells. After eight weeks of treatment with losartan, tumors that expressed AGTR1 shrunk by 30...

Fixed-dose combination offers a convenient option that may help patients reduce steps to reach their blood pressure goals while decreasing patient pill burden(1) PARSIPPANY, N.J., May 13 /PRNewswire/ -- Daiichi Sankyo, Inc. today announced that the United States Food and Drug Administration (FDA) has approved the combination treatment AZOR(R) (amlodipine and olmesartan medoxomil) as initial or 'first-line' therapy in patients likely to need multiple antihypertensive agents to achieve their...

AZTEC Trial First to Examine AZOR Using 24-Hour Ambulatory BP Measures PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that data presented at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the AZOR(R) Trial Evaluating Blood Pressure Reductions and Control (AZTEC) demonstrated that a stepwise amlodipine and olmesartan medoxomil-based titration regimen provided mean 24-hour...

Defended thesis at University of Gothenburg March 20, 2009Clotrimazole is a common ingredient in over-the-counter skin creams. Recent results from the University of Gothenburg, Sweden, now show that it is associated with major environmental risks."The pharmaceuticals and chemicals in everyday use form a mixture in the ocean that has a direct impact on the growth and reproduction of organisms", says scientist Tobias Porsbring.When European authorities assess environmental risks, they...

Nearly every patient who receives care in the intensive care unit (ICU) requires sedation. But, as researchers have discovered, not all sedation medications are equal.Researchers at the University of Vermont found use of the sedative dexmedetomidine for critically ill patients resulted in less time on a ventilator and less delirium compared to patients who were given the more commonly used drug midazolam.During the study, researchers randomized 375 critically ill ICU patients who were...

LAKE FOREST, Ill., Feb. 2 /PRNewswire-FirstCall/ -- The Journal of the American Medical Association (JAMA) has published study results demonstrating Hospira, Inc.'s (NYSE: HSP) alpha-2 agonist Precedex (dexmedetomidine hydrochloride) for intravenous sedation provides comparable effectiveness to commonly used gamma-aminobutyric acid (GABA)-agonist midazolam for greater-than-24-hour sedation of mechanically ventilated patients in the intensive care unit (ICU). According to the...

Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies New data are first to demonstrate direct effect of Zometa to help shrink primary tumors; further evidence of Zometa as a potential anticancer therapy EAST HANOVER, N.J., Dec. 11 /PRNewswire/ -- New data released today demonstrate that the addition of Zometa(R) (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of...